Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity.

In a recent study posted to the bioRxiv* preprint server, researchers observed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) downregulates the expression of major histocompatibility ...

The major histocompatibility complex (MHC) class I antigens are generally ubiquitously expressed and provide the identity to the host organism. 1, 2 Expression of these antigens on the cell surface ...

Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...

Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types. This is an ASCO Meeting Abstract from the ...

T cells have long been studied for their ability to target and eliminate tumor cells. In order for the T cells to do so, the tumors must express antigens not presented by healthy tissues, and the ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.